Publication: 4415

Publication: 4415

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-eligible Patients With Multiple Myeloma: A Pooled Analysis of Patients Aged ≥65 Years From the PERSEUS and GRIFFIN (AFT-29) Studies

Google Scholar

Citation:

Meeting Instance:: IMS 2024
Year:: 2024
Type:: Abstract
Sub type:
Funding:: AFT
Endpoint:: Secondary-not-in-original
Analysis:: Meta-Analysis
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 4881

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Janssen Research and Development
Grants:: AFT

Corr. Author:
Authors:: Paula Rodriguez-Otero Peter M. Voorhees Mario Boccadoro Jacob Laubach Hermann Einsele Douglas Sborov Meletios A. Dimopoulos Annemiek Broijl Roberto Mina Andrew Spencer Fredrik Schjesvold Rebecca Silberman Francesca Gay Luciano Costa Aurore Perrot Yanfang Liu Jianping Wang Anna Sitthi-Amorn Robin Carson Annelore Cortoos Saad Z. Usmani Paul G. Richardson Philippe Moreau Pieter Sonneveld Jonathan L. Kaufman

Networks:: LAPS-AL002, LAPS-MA036, LAPS-NY016, LAPS-UT003, NC002, OH008

Study
Multiple Studies, or Legacy Studies in Alliance Study:: AFT-29 (GRIFFIN)
Phases:: 2

Keywords: